Immunotherapy can reawaken T cells to destroy tumour cells. Modelling of tumour and T-cell interactions suggests why certain tumour cells are targeted and improves predictions of immunotherapy outcome.
This is a preview of subscription content, log in via an institution to check access.
References
Balachandran, V. P. et al. Nature 551, 512–516 (2017).
Łuksza, M. et al. Nature 551, 517–520 (2017).
Robins, H. Curr. Opin. Immunol. 25, 646–652 (2013).
Sharma, P. & Allison, J. P. Science 348, 56–61 (2015).
Schumacher, T. N. & Hacohen, N. Curr. Opin. Immunol. 41, 98–103 (2016).
Carreno, B. M. et al. Science 348, 803–808 (2015).
Ott, P. A. et al. Nature 547, 217–221 (2017).
Sahin, U. et al. Nature 547, 222–226 (2017).
Rights and permissions
About this article
Cite this article
Sarkizova, S., Hacohen, N. How T cells spot tumour cells. Nature 551, 444–446 (2017). https://doi.org/10.1038/d41586-017-07267-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/d41586-017-07267-9
- Springer Nature Limited
This article is cited by
-
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Biomarker Research (2020)
-
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Nature Reviews Cancer (2019)